by The global Lung Cancer Diagnostic and Screening Market is estimated to be valued at US$1,931.0 million in 2023 and is expected to reach US$ (incorporate given market value for 2023) Bn/Mn by 2023, growing at a CAGR of 7.8% during the forecast period (2023-2030), according to a new report published by Coherent Market Insights.
Market Overview:
Lung cancer diagnostic and screening market offers various products and tests used for the identification and detection of lung cancer at an early stage. These products provide accurate and efficient results, helping in better patient management and treatment decision-making. The rising prevalence of lung cancer, coupled with the importance of early diagnosis and screening, is driving the market growth. Lung cancer is one of the leading causes of cancer-related deaths globally, and early detection plays a crucial role in improving patient outcomes. The market offers innovative diagnostic tools and screening procedures that aid in the early detection of lung cancer, ultimately leading to better treatment outcomes.
Market Key Trends:
One key trend driving the lung cancer diagnostic and screening market is the increasing adoption of liquid biopsy techniques. Liquid biopsy is a non-invasive method that allows for the detection of cancer-related genetic mutations and alterations through the analysis of blood samples. This technique offers several advantages over traditional tissue biopsies, such as minimal invasiveness and the ability to track disease progression and treatment response over time. The rising demand for non-invasive diagnostic methods and the potential of liquid biopsy to revolutionize cancer diagnosis and monitoring are expected to drive the market growth in the coming years.
Porter’s Analysis
Threat of New Entrants: The threat of new entrants in the lung cancer diagnostic and screening market is moderate. While the market presents significant opportunities for new players due to the increasing prevalence of lung cancer globally, there are also several barriers to entry. These include high research and development costs, stringent regulatory requirements, and the need for established distribution networks. Additionally, well-established companies already hold a significant market share, creating a barrier for new entrants.
Bargaining Power of Buyers: The bargaining power of buyers in the lung cancer diagnostic and screening market is moderate. While buyers, such as hospitals and diagnostic laboratories, hold some power due to their ability to choose from multiple suppliers, the specialized nature of lung cancer diagnostic tests limits their options. Suppliers often offer comprehensive diagnostic solutions, making it difficult for buyers to switch between different providers. Additionally, the critical nature of lung cancer diagnostics and the need for accurate and reliable tests reduce buyer power.
Bargaining Power of Suppliers: The bargaining power of suppliers in the lung cancer diagnostic and screening market is moderate. Suppliers of diagnostic equipment and test kits hold some power due to their specialized and unique products. However, the presence of multiple suppliers and intense competition in the market limits their ability to exert significant control over prices. Moreover, buyers in the market have the option to switch between different suppliers based on factors such as cost, quality, and reliability.
Threat of New Substitutes: The threat of new substitutes in the lung cancer diagnostic and screening market is low. Currently, there are limited alternatives available for diagnosing and screening lung cancer. Traditional methods, such as biopsy and imaging tests, remain the primary diagnostic techniques. While there is ongoing research and development in areas such as liquid biopsies and genetic testing, these alternatives are still in the early stages of development and adoption.
Competitive Rivalry: The competitive rivalry in the lung cancer diagnostic and screening market is intense. Several key players, such as Abbott, Illumina, Thermo Fischer Scientific, and Roche, dominate the market. These companies have a strong presence and a wide range of products and services. Additionally, there is continuous innovation and technological advancements, which further intensify the competition among market players.
Key Takeaways
The Global Lung Cancer Diagnostic And Screening Market Size is expected to witness high growth, exhibiting a CAGR of 7.8% over the forecast period. This growth is primarily driven by the increasing prevalence of lung cancer globally, especially in developing countries, due to factors such as smoking, pollution, and genetic predisposition. Additionally, advancements in diagnostic technologies, such as next-generation sequencing and liquid biopsies, are further fueling market growth.
Regionally, North America is the fastest-growing and dominating region in the lung cancer diagnostic and screening market. The region’s dominance can be attributed to factors such as well-established healthcare infrastructure, high awareness about lung cancer screening, and the presence of key market players. Moreover, increasing government initiatives and funding for cancer care and research in the region are also contributing to market growth.
Key players operating in the lung cancer diagnostic and screening market include Abbott, Illumina, Thermo Fischer Scientific, QIAGEN, Quest Diagnostics Incorporated, NeoGenomics, NanoString, Myriad Genetics Inc., F. Hoffmann-La Roche Ltd, Danaher, Agilent Technologies, AstraZeneca, Sanofi, and Janssen Pharmaceuticals. These companies have a strong market presence and are investing in research and development to introduce innovative products and expand their market share.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
